Clinical Trial Update: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features [Phase 3]

View source ↗

Summary

Phase III randomized trial evaluating adjuvant datopotamab deruxtecan (Dato-DXd) in combination with rilvegostomig or rilvegostomig monotherapy versus standard …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Non-small Cell Lung Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)
• Rilvegostomig (rilvegostomig)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING